Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 8;13:150. doi: 10.1186/s12967-015-0509-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Yamamoto et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Anti-angiogenic effects of combination therapy with sorafenib and everolimus in PTEN-deficient prostate cancer. Assays of MVD assessed in prostate tumors from mice with CNPC and CRPC after drug interventions. (A) Representative images showing CD31 immunostaining of prostate tumors after the indicated treatment. Scale bars represent 100 μm. (B) Quantitative analysis of MVD according to the presence of CD31-positive microvessels. Values are expressed as the mean ± s.e., *P < 0.05.